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Introduction
Prostate cancer (PCa) accounts for 29% of all diagnosed malignancies among men in the United States. An estimated 241,740 men will be diagnosed with PCA in 2013, and 28,170 men will die of it, making it the 2 nd most common cause of cancer death{1} . The number of men ≥65 years is expected to increase 4-fold by 2050 {2}. These statistics portend a substantial increase in the number of men who will be diagnosed with PCa and who will require treatment for their malignancy. To control and target PCa, several signaling pathways need to be tested for therapeutic potential. One such pathway that has been implicated in prostate tumoriogenesis is PTEN/PI3K/AKT signaling pathway, Somatic PTEN alterations such as homozygous deletions,] Loss of Heterozygosity (LOH) and inactivating mutations, have been shown in both localized and metastatic PCa. Point mutations in primary tumors (1/40){3-4}, (5/37){5}; homozygous deletions (8/60){6}; LOH in 23/80 primary tumors with either deletion or mutation of the remaining allele in 10/23 LOH+ tumors was reported{7}. Thus, a substantial minority ( 15%) of primary tumors harbors PTEN mutations. Formation of complex between AR, p85α and Src is required for androgen stimulated PI3K/AKT activation leading to cell survival{8}. Mutations of AR in PCa are rare in early stages, however, the frequency of mutations increase in the advanced, androgen independent tumors {9}. AR mutations lead to decreased specificity of ligand binding and inappropriate receptor activation by estrogens, progestins, adrenal androgens, glucocorticoids and/or AR antagonists. These mutations may still possess the ability to induce the PI3K/AKT activity. AR represses CaMKII which in turn repress the PI3K/AKT activity and loss of AR activity by AD results in induction of PI3K/AKT activity{10}. Thus, there are atleast two different mechanisms by which AR signaling regulates PI3K/AKT signaling pathway. microRNAs (miRNAs), small non-coding RNAs, have emerged as key regulators of a large number of genes. The deregulation of the cellular "miRNome" in prostate cancer has been connected with multiple tumor-promoting activities such as aberrant activation of growth signals (such as PI3K/AKT signaling, activation of AR signaling), anti-apoptotic effects, prometastatic mechanisms, alteration of the androgen receptor pathway, and regulation of the cancer stem cell phenotype. With the elucidation of molecular mechanisms controlling and controlled by microRNAs, investigations are underway, in an attempt to exploit these molecules in the clinical setting. The knowledge gleaned from such studies could make the multifaceted biological activity of microRNAs an attractive candidate as anticancer agents{11}. With advances in expression profiling microarray analysis on miRNAs has become fast and easy approach to detect distinctive signatures for specific tissues or disorders{12}. In Cancer, the association between miRNA and oncogene regulation has been reported and miRNA's involvement in cancers has been identified through microarray experiments{13}. Computational predictions estimate that miRNAs regulate about 60% of all human protein coding genes{14} affecting several cellular processes such as diffentiation, growth and apoptotis{15}. RNA silencing is a highly conserved gene regulatory mechanism present in almost all eukaryotic organisms. miRNA and SiRNA can inhibit gene expression in a sequence specific manner. Aberrant miRNA expression is a hallmark of several different types of cancer including Prostate cancer. miRNA inhibits the expression of many genes suggesting that comprehensive regulation can be achieved by antagonizing or overexpressing a single miRNA. We have uncovered a novel mechanism of miRNA processing by AGO family of silencing proteins through PI3K/AKT signaling. Analysis of the several known components of miRNA biogenesis for consensus AKT phosphorylation and 14-3-3 binding sites (RSXpSXP and RXY/FXpSXP{16}) identified their presence in AGO1, 3 Figure 1 . It is hypothesized that "AKT regulates the RNA-induced silencing Complex (RISC) activity through the phosphorylation of AGO proteins in Prostate carcinoma cells".
Since we could not isolate miRNAs by immunoprecipitating the AGO protein complex we modified our hypothesis, KSRP is a single strand nucleic acid binding protein that controls gene expression at multiple levels. Binding of the human KSRP protein to let-7 miRNA precursors positively regulates their processing to mature let-7 (18) . KSRP has an Akt phosphorylation site in its primary As shown has-let7b* is the most up regulated miRNA and hsamiRNA 181c is the most down-regulated miRNA "Heatmap was generated using fold change differences between "Control" and "Test(TCN-trearted" groups" by Western immunoblot. Although we could not detect presence of Tau isoform of 14-3-3 in the input or flow through it was enriched in the elute (Figure 2 ). We still have to identify the isoform of AGO protein involved in this interaction.
AKT regulates expression of miRNA in Prostate carcinoma cells. In order differentially expressed between control untreated PC3 cells and 40μM Triciribine treated PC3 As shown DDIT4 is the most up regulated mRNA and SERPINB2 is the most down-regulated mRNA "Heatmap was generated using fold change differences between "Control" and "Test(TCN-trearted" "
For each sample, the preamplification reactions A and B were diluted and each reaction was combined with Taqman ® Gene-Expression Master Mix (Applied Biosystems) divided into eight aliquots and each aliquot was added to one of the eight sample ports of the TaqMan ® Array A or B (v2.0), respectively. The TaqMan ® Array Human miRNA Card Set v2.0 enables detection of 667 human miRNAs, 3 miRNA endogenous reference controls and 1 miRNA assay not related to human as a negative control. The real-time polymerase chain reaction (PCR) reactions were run according to the manufacturer's instructions. RealTime Statminer Software (Integromics, Philadelphia, PA, USA) was used to analyze the data. The global geometric mean of all expressed miRNA assays was used to normalize the data.{21}. Of the ~300 miRNA showing changes when cells were treated with 40μM Triciribine and the miRNAs showing atleast two-fold change were selected with a significance of atleast P<0.05 by BenjaminiHochberg and Westfall & Young methods as shown in Figure 4 and Table 1 & 2. According to this analysis, let-7b* was the miRNA that was highly upregulated (4.34 folds in Triciribine treated PC3 cells compared to control at a significance of p< 0.005. Similarly hsa-miR-181c was the most down regulated miRNA in response to triciribine treatment in PC3 cells compared to control PC3 cells. (Table 1 & 
2).
Microarray for expression of mRNA: Expression data obtained by hybridizing samples to HumanHT-12 V4_0_R1 array platform (Illumina) were loaded on GeneSpring 12.5 GX (Agilent Technologies, Santa Clara, CA, USA). The raw intensities from the array were normalized using 'Quantile normalization' method and log (base 2) transformed. The normalized data was subjected to statistical analysis using paired Student's T-test (two-class comparisons). All significant and differentially expressed (DE) genes were subset using P-value ≤ 0.005 and fold change Correlation between miRNA and mRNA expression profiles to identify a potential model for regulation by PI3K/AKT/Ago/14-3-3 pathway.We carried out Chromatin IP assay for total AGO protein-associated miRNA.We found the quality of total RBA isolated to be very poor.Therefore this approach was abandoned. We took a different approach to identify miRNAassociated with PI3K/AKT signaling pathway. Since the results so far did not give the relationship network between miRNA and mRNA expression we sought to carry out a pearson correlation to identify a potential model to test the role of AKT-mediated phosphorylation of AGO proteins in differential miRNA processing in prostate carcinoma cells. All significant miRNAs (P-value (BenjaminiHochberg corrected) ≤ 0.05) were subset and searched against miRWalk database (http://www.umm.uni-heidelberg.de/apps/zmf/mirwalk/index.html) for predicted and validated microRNA targets {21}. Expression data for all the significant differentially expressed genes (P-value ≤ 0.05) among these gene targets for each miRNA were extracted from the Illumina gene expression microarray. The target genes were grouped into 4 categories (Up/down; Down/Up; Down/Down and Up/Up) depending on correlation to miRNA to mRNA expression patterns.{22}. Down/Down and Up/Up will probably be due to coregulation of miRNA and mRNA, either up or down regulation. Up/down and Down/Up will most likely be due to inverse correlation between miRNA and mRNA. We selected the most up regulated (HSA-miRNA-let7b 4.34) and down regulated miRNA (HAS-miRNA-181c;-3.54) and identified the top 10 down regulated and up regulated mRNAs respectively by Pearsons correlation. (Table  # 5 and 6 ). Using this strategy we could narrow down two networks viz.1. let7b-NFκB1 causing down regulation of NFkB1 with triciribine which could regulate NfκB signaling network. 2. let7b-cldn1 causing down regulation of claudin1 with triciribine which could regulate tight junctions in prostate carcinoma cells. These two pathways are being pursued. Thus, let-7b could regulate the survival(through NFκB) and metastasis ( through claudin 1) of prostate carcinoma cells and could be a potential target for prostate cancer therapy. Using this strategy we eliminated miRNA and mRNA's that were coregulated either up or down. Table #5 : Top 10 mRNAs down regulated with increased expression of let7b in response to 40μM AKT inhibitor triciribine. Claudin1 (CLDN1) and NFκB (p50) mRNA were validated targets of let-7b down regulated by 5.54 and 3.96 folds. Table #6 : Top 10 mRNAs up regulated with decreased expression of miRNA181c in response to 40μM AKT inhibitor triciribine. ERBB2(HER2/Neu) and PML(promyelocytic leukemia) mRNA were validated targets of miRNA-181c up regulated by 1.74 and 1.59 folds. For the sake of time and expenditure we limited our studies to these two networks. We did not further explore miR-181c and its targets.
Experimental Validation of downregulation of CLDN1 and NFkBp50 by real time RT-PCR and Western blotting.
We used quantitative Rt-PCR and western blot to validate changes seen in our microarray experiments. We used Pfaffl method {23} to quantify changes in the expression of Let7/b miRNA, CLDN1 and NFKB1(p50) mRNA. As seen with microarrays there was approximately 4.09 fold upregulation of let7b MiRNA and 4.25 and 3.466 fold down regulation of Claudin1 (CLDN1) and NFkB1 (p50) respectively( Figure 5 ). In order to find out if the changes in expression seen with microarrays and quantitative RT-PCR translated into qualitative changes in protein expression of CLDN1 and NFKB1(p50) Western immunoblot was carried out. We found similar qualitative changes in the expression of CLDN1 and NFKB1(p50) both in the Du145 and PC3 cells suggesting a novel mechanism of regulation of these genes in prostate cancer.
Research Accomplishments.
Luciferase reporter to study the regulation of Let7b miRNA expression. In order to study the regulation of let7b expression we cloned the let 7b binding site into psiCheck 2.2. We can now study the regulation of let7b miRNA expression by different components of PI3K/AKT signaling in future. 
Reportable Outcomes
This project started with the hypothesis "AKT regulates the RNA-induced silencing Complex (RISC) activity through the phosphorylation of AGO proteins in Prostate carcinoma cells". We could not get good quality miRNA using immunoprecipitation of total AGO proteins or by immunoprecipitation of biotynylated total RNA (including miRNA and mRNA). This led to a drastic change in our direction of research. Using the GeneGo analysis.we identified epithelial-mesenchymal transition as a mechanism that is affected with TCN-mediated inhibition of AKT signaling. . However, we could not confirm this mechanism in our studies. We hypothesized that altered miRNA will in turn effect the levels of mRNA targets. We treated prostate carcinoma cells (PC3) with 40 μM AKT inhibitor V, Triciribine.Total RNA was isolated and miRNA and mRNA expression analysis in prostate carcinoma cells (PC3) was carried out to identify the miRNA-mRNA correlation matrices using Pearson Correlation in response to cells treated with AKT inhibitor (Triciribine). We also identified the miRNA-mRNA correlation matrices using Pearson Correlation in response to cells treated with AKT inhibitor (Triciribine). These matrices were further classified into four groups viz., I. miRNA up mRNA down. II miRNA down mRNA up. III. Both miRNA and mRNA up. IV. Both miRNA and mRNA down.. Based on these analysis and latest findings in miRNA regulation (18) ) and lack of obtaining results using AGO protein Immunoprecipitationswe came up with a model (Figure 7 ) wherein PI3K/AKT phosphorylates KSRP which can then bind to 14-3-3 zeta and sequesters it away from its function leading to repression of expression of Let7b miRNA which in turn downregulates the expression of CLDN1 and NFkBp50 mRNA (Figure 8 ). CLDN1 AND NFkb1(p50) mRNA are validated targets of Let7b (BLAT alignment against genome suggests intronic hits in both genes( Figure   7 ) Figure 7 . Using the BLAT sequence alignment we found let 7b targets in both CLDN1 and NFkB1(p50) mRNA. 
